Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs Jul 19, 2022
Awakn Life Sciences Appoints Biotech and Investment Veteran Dennis Purcell as a Special Advisor to the CEO Jun 7, 2022
Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program Jun 3, 2022
Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major… May 31, 2022
Awakn Life Sciences CEO, Anthony Tennyson, Joins Dustin Robinson of Iter Investments for ‘The Investor… May 24, 2022
Awakn Life Sciences Completes World’s First Ketamine Treatment Study for a Range of Behavioral Addictions May 19, 2022
Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted… May 16, 2022
